Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study
{{output}}
Objectives: To study the efficacy of rituximab in active rheumatoid arthritis (RA) patients refractory to disease modifying anti-rheumatic drugs (DMARDs) including the tumor necrosis factor (TNF)-alpha antagonists. ... ...
